peg-IFN-α

DRUG3 trials

Sponsors

University of Michigan Rogel Cancer Center, Fujian Shengdi Pharmaceutical Co., Ltd., Minghui Li

Conditions

Acute Myeloid LeukemiaChronic Hepatitis B

Phase 1

Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia

CompletedNCT02328755

University of Michigan Rogel Cancer CenterAcute Myeloid Leukemia

Start: 2015-01-31End: 2019-03-25Updated: 2021-10-06

Phase 2

A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B

RecruitingNCT06425341

Fujian Shengdi Pharmaceutical Co., Ltd.Chronic Hepatitis B

Start: 2024-06-06End: 2027-01-19Target: 369Updated: 2025-11-17

Unknown Phase

Exploring the Genome-wide Association Study of the Population With Clinical Cure Advantage in the Treatment of Chronic Hepatitis B With Long-acting Interferon

RecruitingNCT06696664

Minghui LiChronic Hepatitis B

Start: 2024-08-01End: 2026-03-31Target: 120Updated: 2024-11-20

Related Papers

Type 1 interferon to prevent leukemia relapse after allogeneic transplantation

Blood Advances2021-10-0523 citations